Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million

Reuters

Feb 18

Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million

Medifast Inc. reported full-year (FY) 2025 revenue of USD 385.79 million, with a net loss of USD 18.7 million, or USD 1.70 per diluted share. The net loss includes a tax provision charge related to a non-cash valuation allowance on the company’s deferred tax balance amounting to USD 12.1 million, or USD 1.10 per diluted share. For the fourth quarter (Q4) 2025, revenue was USD 75.10 million with a loss from operations of USD 7.80 million. Cash, cash equivalents, and investment securities totaled USD 167.3 million, with no debt at year-end. Medifast highlighted a significant increase in coach-led meetings and noted that coach productivity turned positive year-over-year in Q4 for the first time since 2022, which management views as a positive indicator for future performance as the company pivots its strategy toward optimal metabolic health.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medifast Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602171605BIZWIRE_USPR_____20260217_BW997703) on February 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612576460"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612576460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612576460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612576460","market":"fut","top_or_hot":-1,"title":"Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medifast Inc. reported full-year (FY) 2025 revenue of USD 385.79 million, with a net loss of USD 18.7 million, or USD 1.70 per diluted share. The net loss includes a tax provision charge related to a non-cash valuation allowance on the company’s deferred tax balance amounting to USD 12.1 million, or USD 1.10 per diluted share. For the fourth quarter (Q4) 2025, revenue was USD 75.10 million with a loss from operations of USD 7.80 million. Cash, cash equivalents, and investment securities totaled USD 167.3 million, with no debt at year-end. Medifast highlighted a significant increase in coach-led meetings and noted that coach productivity turned positive year-over-year in Q4 for the first time since 2022, which management views as a positive indicator for future performance as the company pivots its strategy toward optimal metabolic health.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medifast Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602171605BIZWIRE_USPR_____20260217_BW997703) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Medifast Inc. reported full-year (FY) 2025 revenue of USD 385.79 million, with a net loss of USD 18.7 million, or USD 1.70 per diluted share. The net loss includes a tax provision charge related to a non-cash valuation allowance on the company’s deferred tax balance amounting to USD 12.1 million, or USD 1.10 per diluted share. For the fourth quarter (Q4) 2025, revenue was USD 75.10 million with a loss from operations of USD 7.80 million. Cash, cash equivalents, and investment securities totaled USD 167.3 million, with no debt at year-end. Medifast highlighted a significant increase in coach-led meetings and noted that coach productivity turned positive year-over-year in Q4 for the first time since 2022, which management views as a positive indicator for future performance as the company pivots its strategy toward optimal metabolic health.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medifast Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602171605BIZWIRE_USPR_____20260217_BW997703) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8n9Rd2:1","article_id":"2612576460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612576460","pubTimestamp":1771362372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medifast Inc. reported full-year  2025 revenue of USD 385.79 million, with a net loss of USD 18.7 million, or USD 1.70 per diluted share. The net loss includes a tax provision charge related to a non-cash valuation allowance on the company’s deferred tax balance amounting to USD 12.1 million, or USD 1.10 per diluted share. For the fourth quarter  2025, revenue was USD 75.10 million with a loss from operations of USD 7.80 million. Cash, cash equivalents, and investment securities totaled USD 167.3 million, with no debt at year-end. Medifast highlighted a significant increase in coach-led meetings and noted that coach productivity turned positive year-over-year in Q4 for the first time since 2022, which management views as a positive indicator for future performance as the company pivots its strategy toward optimal metabolic health.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4183":"个人用品","MED":"快验保"},"translate_title":"快验保第四季度净利润亏损-1810万美元，收入下降36.9%至7510万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MED":0.9},"content_text":"Medifast Q4 net income posts USD -18.1 million loss as revenue drops 36.9 percent to USD 75.1 million\n    \n\n        Medifast Inc. reported full-year (FY) 2025 revenue of USD 385.79 million, with a net loss of USD 18.7 million, or USD 1.70 per diluted share. The net loss includes a tax provision charge related to a non-cash valuation allowance on the company’s deferred tax balance amounting to USD 12.1 million, or USD 1.10 per diluted share. For the fourth quarter (Q4) 2025, revenue was USD 75.10 million with a loss from operations of USD 7.80 million. Cash, cash equivalents, and investment securities totaled USD 167.3 million, with no debt at year-end. Medifast highlighted a significant increase in coach-led meetings and noted that coach productivity turned positive year-over-year in Q4 for the first time since 2022, which management views as a positive indicator for future performance as the company pivots its strategy toward optimal metabolic health.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medifast Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602171605BIZWIRE_USPR_____20260217_BW997703) on February 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}